Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review-Reference-Cited by-同舟云学术

Risk-of-bias assessment using Cochrane's revised tool for randomized trials (RoB 2) was useful but challenging and resource-intensive: observations from a systematic review

Published:2023-09 Issue: Volume:161 Page:39-45
ISSN:0895-4356
Container-title:Journal of Clinical Epidemiology
language:en
Short-container-title:Journal of Clinical Epidemiology

Author:

Crocker Thomas Frederick^ORCID,Lam Natalie^ORCID,Jordão Magda^ORCID,Brundle Caroline,Prescott Matthew,Forster Anne,Ensor Joie^ORCID,Gladman John^ORCID,Clegg Andrew

Funder

Health Technology Assessment Programme

National Institute for Health and Care Research

Publisher

Elsevier BV

Subject

Epidemiology

Reference17 articles.

1. Cochrane handbook for systematic reviews of interventions;Higgins,2019

2. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias);Guyatt;J Clin Epidemiol,2011

3. Assessing risk of bias in included studies;Higgins,2008

4. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials;Higgins;BMJ,2011

5. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews;Jørgensen;Syst Rev,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of yoga for posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials;Psychiatry Research;2024-10

2. Zero‐ and few‐shot prompting of generative large language models provides weak assessment of risk of bias in clinical trials;Research Synthesis Methods;2024-08-23

3. Research Quality of Clinical Trials Reported for Foods with Function Claims in Japan, 2023–2024: Evaluation Based on a Revised Tool to Assess Risk of Bias in Randomized Trials;Nutrients;2024-08-17

4. Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol;PLOS ONE;2024-08-01

5. Common challenges and suggestions for risk of bias tool development: a systematic review of methodological studies;Journal of Clinical Epidemiology;2024-07